Reducing research waste by promoting informed responses to invitations to participate in clinical trials by Gillies, Katie et al.
COMMENTARY Open Access
Reducing research waste by promoting
informed responses to invitations to
participate in clinical trials
Katie Gillies1* , Iain Chalmers2, Paul Glasziou3, Diana Elbourne4, Jim Elliott5 and Shaun Treweek1
Abstract
Poor recruitment to, and retention in, clinical trials is a source of research waste that could be reduced by more
informed choices about participation. Barriers to effective recruitment and retention can be wide-ranging but
relevance of the questions being addressed by trials and the outcomes that they are assessing are key for potential
participants. Decisions about trial participation should be informed by general and trial-specific information and by
considering broader assessments of ‘informedness’ and how they impact on both recruitment and retention. We
suggest that more informed decisions about trial participation should encourage personally appropriate decisions,
increase recruitment and retention, and reduce research waste and increase its value.
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Background
Poor recruitment to, and retention in, clinical trials can
be important sources of waste in clinical research [1–4].
This source of waste may result from, for example: regu-
latory barriers; inappropriate study design, particularly
inclusion criteria; failure to use effective and efficient
recruitment and retention strategies; negative attitude of
patients and clinicians to trials; and the (ir)relevance of
the study question to patients and clinicians.
The reasons for poor recruitment to, and retention in,
clinical trials need to be diagnosed so that appropriate
strategies for prevention and treatment can be imple-
mented. Evidence for effective strategies is currently
limited: the Cochrane recruitment review, for example,
identified 72 wide-ranging recruitment interventions, but
only three of them (open vs. blinded trials; telephoning
non-responders; a particular, structured process for devel-
oping participant information leaflets) are supported by
high-certainty evidence to improve recruitment [5]. The
sister Cochrane review on strategies to improve retention
identified more than 50 interventions (the majority focus-
sing on improving questionnaire return), of which only
monetary incentives were shown to be effective [6]. Inves-
tigating how interventions to improve recruitment influ-
ence retention was evaluated by only one trial included in
both of these reviews [7].
Informed agreement to participate and stay in a clin-
ical trial is unlikely if the research question it addresses,
the interventions it is comparing and the measures of
treatment outcomes planned are of little or no interest
to potential participants and their clinicians. Four sys-
tematic reviews [8–11] have found perceived personal
benefit to be a key motivator for taking part in a trial: if
it is not clear that a trial has at least the prospect of
benefit, potential participants are unlikely to become ac-
tual participants. By contrast, if the questions addressed
and the trial’s design have been chosen by a multidiscip-
linary team, including patients and healthcare profes-
sionals [12], it is reasonable to expect that the study will
receive support from potential participants and health-
care professionals. Priority setting exercises involving pa-
tients, healthcare professionals, and other relevant
stakeholders are now becoming a widely accepted
method in health services’ research to identify and pri-
oritise research questions in key clinical areas (http://
www.jla.nihr.ac.uk/about-the-james-lind-alliance/about-
psps.htm). These ‘Priority Setting Partnerships’ ensure
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relevance, acceptability, and importance of questions to
all stakeholders.
For example, people with asthma and the clinicians
caring for them agreed some years ago that it was
important to address uncertainties about the value of
breathing-retraining programmes [13]. An appropriately
designed randomised trial was commissioned to address
this uncertainty. The trial recruited the intended number
of participants within the planned timescale and showed
that breathing-retraining programmes improve quality of
life and that they can be delivered cost-effectively using
self-guided audiovisual media [14]. The Football Fans in
Training trial also recruited to target and retained well
(92%), in part because of the involvement of future users
of the results – football clubs – in design decisions [15].
Informed consent to participate in clinical trials
A book about clinical research written for the public (‘Test-
ing Treatments’) advised readers only to accept invitations
to participate in clinical trials if the researchers could show
that they were addressing important uncertainties [16].
There are two components to important uncertainties: (1)
that systematic reviews of all current relevant research have
shown substantive residual uncertainties about the effects
(benefits or harms) of the treatment(s); and (2) that resolv-
ing those uncertainties would be important to a body of
patients and clinicians. It is clearly not in the public interest
to increase recruitment to clinical trials addressing ques-
tions that are not important to patients [17]. This implies
that potential participants in clinical trials need to be dis-
cerning when deciding which trials to support. To achieve
this, they need to have both general (related to the trial’s
endeavour more broadly) and specific knowledge (of rele-
vance to the particular trial for which they are considering
participation).
The general knowledge needed by potential partici-
pants is an awareness of the damage that has been done
by the continued use of inadequately tested treatments
in the past, and that this remains a problem with today’s
treatments [16].
The specific pieces of information needed by potential
participants in a particular trial are the current basis of
the treatment(s) and the residual uncertainties as dem-
onstrated by systematic reviews of all previous relevant
research about their effects (benefits or harms). Whilst
there is currently a lack of empirical evidence about
what information potential participants want when
facing a decision about participation and even less about
what they want during the research [18], the exact
content of this information should be decided and co-
produced with patient and clinician partners during trial
design. Table 1 lists both general and specific questions
which may be relevant to ensuring informed decisions
about participation in clinical trials.
Conclusions
Can potential trial participants be properly informed
without having general and trial-specific knowledge?
Evidence from a systematic review highlights a lack of
understanding on general items (e.g. randomisation,
voluntariness) and trial-specific items (e.g. overall aim,
treatment risks and benefits) amongst research partici-
pants [19]. Yet, participant-reported measures of in-
formed consent often do not attend to assessments that
go beyond understanding – leaving unanswered the
question of whether consent was an informed decision
[20]. What seems to be missing is a body of evidence
derived from observing interactions between trial
recruiters and potential participants, and information
about whether both parties have a good grasp of the key
concepts needed to support informed choices [21]. The
Quintet Recruitment Intervention recommends record-
ing conversations between recruiters and potential
participants to learn more about the recruitment conver-
sation and how that conversation could be improved
[22]. However, it should be noted that requests to record
these conversations have sometimes been rejected by a
substantial minority of potential trial participants [23].
Research on participant information leaflets, a key part
of the recruitment process, has found that most leaflets
do not provide the information needed to support
Table 1 Questions identifying general and specific information
needed to make informed choices about participating in a trial
General
• Do they know that new treatments are about as likely to be worse
as they are to be better than alternative existing treatments [17]?
• Do they understand why random allocation to treatment comparison
groups is used in ‘fair tests’, and why blinding outcome assessment is
desirable if possible [15]?
• Are they aware of the importance of providing required outcome
data to contribute to analysis?
• Are they aware that insufficiently large studies and the failure to
report some studies have resulted in lethally mistaken beliefs about
the effects of treatments [15]?
Specific
• Are potential participants told whether similar patients to them
have contributed to the design of the trial?
• Are the questions being addressed by the trial relevant to their
personal interests?
• Are they supported to make decisions appropriate for them as
individuals?
• Are they told about the requirements of the trial as a whole (i.e. the
work associated with taking part and completing the trial) and not
just the recruitment process?
• Are they satisfied that those collecting, analysing and interpreting
the evidence yielded by the trial are sufficiently free of competing
interests?
• Have they been assured that a full report of the trial will be
published?
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informed decision-making [24], and the same may well
be true of recruitment discussions. Preliminary work to
develop and evaluate decision aids (tools that aim to
support informed choices about options) for trial partici-
pation has shown promise by supporting decisions that
align with individual’s values and expectations [25–27].
Whether and how this translates to overall improve-
ments in recruitment and retention requires further
investigation. Work is also underway to explore and
agree which outcomes to use to evaluate attempts to
improve the consent process [20]. Consent seems in-
creasingly likely in future to be sought using digital
media, a development that will offer both challenges and
opportunities [28].
Researchers and clinicians could engage more effect-
ively with patients and the public to promote trials.
Evidence from a recent survey revealed that only 37% of
the public said that they trusted evidence from medical
research [29]. This finding may be one of the reasons for
poor recruitment in clinical trials and the resulting waste
of resources. A potential opportunity to address this lack
of trust (and other improvements in recruitment and re-
tention) could lie in bringing together activated,
empowered, patient groups through campaigns such as
#wearenotwaiting [30]. This group of activated patients
could act as peer educators allaying myths and misun-
derstandings about trials generally within patient
communities. International efforts to improve Patient
and Public Involvement (PPI) are also gathering speed
with the development of initiatives such as the #globalP-
PInetwork. A key priority emerging from the latter is the
need to develop training particularly for patients and the
public working on clinical trials [31].
There are already relevant learning resources available,
for example, those made available through www.testing-
treatments.org, and research has shown that it is
possible to teach primary school children and adults to
apply some of the key concepts needed to inform treat-
ment choices [32, 33]. Wider acquisition of these skills
should help people to make informed treatment choices,
but it may also help them to make more informed
decisions about whether to participate in clinical trials
when there are uncertainties about the relative merits of
the different treatment options open to them.
The need for informed decision-making in response to
invitations to participate in clinical trials remains when a
decision to take part is made on behalf of an individual
(e.g. because of cognitive impairment) or on behalf of a
population (e.g. a regional evaluation of a screening
intervention). In these circumstances it falls to staff at
the institutions invited to participate in research to
ensure that they are aware of the evidence that proposed
studies will address confirmed, important uncertainties
about the effects of treatments [34]. They too need both
general and trial-specific knowledge to make their
decisions.
Potential participants in clinical trials need to be
appropriately informed and discerning when deciding
which trials to support. Informed decisions seem likely
to promote successful recruitment and retention, and
thus to reduce waste in clinical research. Public capacity
to make sufficiently informed decisions will depend on
greater efforts to promote the general knowledge needed
to assess evidence of important uncertainties and how
they should be addressed. This may be achieved, for
example, through raising public awareness of trials and
fostering critical appraisal of evidence. Also needed are
better means to provide the specific knowledge required
for decision-making about individual trials, which will
likely require development of decision-support interven-
tions. Whilst researchers will be key in realising these
benefits, failure to involve patients and healthcare
professionals may result in avoidable inefficiency and
waste in clinical trials.
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